Macomics Presents its ENIGMAC™ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
17 avr. 2023 13h30 HE
|
Macomics Limited
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery has presented data demonstrating the power of its...
Antibody Testing Market to Grow US$17.7 Billion by 2033, Driven by Growing Demand for Accurate Diagnostics | Persistence Market Research
13 avr. 2023 12h00 HE
|
Persistence Market Research
New York, April 13, 2023 (GLOBE NEWSWIRE) -- The global Antibody Testing Market is expected to generate US$ 7.9 billion in revenue by 2022, and is projected to grow at a CAGR of 7.6% to US$ 17.7...
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
28 mars 2023 08h30 HE
|
Compass Therapeutics
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
27 févr. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced...
Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
02 févr. 2023 08h30 HE
|
Compass Therapeutics
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
19 janv. 2023 17h00 HE
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
14 déc. 2022 08h30 HE
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
The Top 6 Global Manufacturer and manufacturing capabilities in Antibody market 2023 | forecast to a readjusted size of USD 13230 million by 2028 with a CAGR of 5.1%
16 nov. 2022 02h06 HE
|
Proficient Market Insights
Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Antibody Market" research report focus on overall information that can help to take decisions on current market situation. The Antibody market report...
Compass Therapeutics to Present at Upcoming Investment Conferences
08 nov. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics Announces $80 Million Private Placement
02 nov. 2022 09h06 HE
|
Compass Therapeutics
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to...